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Abstract
Objectives: integration of hiV and non-communicable disease services improves the quality and efficiency of care in 
low- and middle-income countries (lMics). We aimed to describe current practices for the screening and management 
of atherosclerotic cardiovascular disease (ascVD) among adult hiV clinics in asia.
Methods: sixteen lMic sites included in the international epidemiology Databases to evaluate aiDs – asia-Pacific 
network were surveyed.
Results:  sites were mostly (81%) based in urban public referral hospitals. half had protocols to assess tobacco and 
alcohol use. Protocols for assessing physical inactivity and obesity were in place at 31% and 38% of sites, respectively. 
Most sites provided educational material on ascVD risk factors (between 56% and 75% depending on risk factors). a total 
of 94% reported performing routine screening for hypertension, 100% for hyperlipidaemia and 88% for diabetes. routine 
ascVD risk assessment was reported by 94% of sites. Protocols for the management of hypertension, hyperlipidaemia, 
diabetes, high ascVD risk and chronic ischaemic stroke were in place at 50%, 69%, 56%, 19% and 38% of sites, 
respectively. Blood pressure monitoring was free for patients at 69% of sites; however, most required patients to pay 
some or all the costs for other ascVD-related procedures. Medications available in the clinic or within the same facility 
included angiotensin-converting enzyme inhibitors (81%), statins (94%) and sulphonylureas (94%).
Conclusion: The consistent availability of clinical screening, diagnostic testing and procedures and the availability of 
ascVD medications in the asian lMic clinics surveyed are strengths that should be leveraged to improve the implementation 
of cardiovascular care protocols.
Keywords: hiV, cardiovascular disease, atherosclerosis, hypertension, asia
Introduction
While aiDs-related infections, malignancies and deaths have 
declined among people living with hiV (PlhiV) in the antiretroviral 
therapy (arT) era, there has been a concomitant increase in 
non-aiDs-related causes of death [1–3]. This trend is consistent 
with the dramatic global increase in population rates of 
non-communicable disease over the past three decades [4]; 
however, many studies now show that PlhiV experience a dis-
proportionate amount of this burden [5–7]. although partly due 
to the high prevalence of traditional risk factors among PlhiV, 
the increase in non-aiDs-related causes of death may also be 
associated with the persistent low-level inflammation induced 
by long-term arT and hiV infection itself [8].
atherosclerotic cardiovascular disease (ascVD) is now a leading 
cause of non-aiDs-related death among people on arT [9–11]. 
however, in many low- and middle-income countries (lMics), 
ascVD is managed episodically, thereby placing patients at risk 
of long-term complications [12]. in contrast, hiV programmes 
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in lMics have proven very successful in establishing long-term 
care models that focus on continuity of care and retention, routine 
monitoring, and reduction in hiV transmission risk. integration 
of hiV and non-communicable disease services has been shown 
to improve the quality and efficiency of care among PlhiV in 
lMics [13,14], and was recommended by the World health 
Organization in their action plan for the prevention and control 
of non-communicable diseases in southeast asia from 2013 to 
2020 [15]. UnaiDs estimates that 5.9 million people are cur-
rently living with hiV in asia [16]. nevertheless, data remain 
limited with regard to the infrastructure and human resources 
available for non-communicable disease care among hiV clinics 
in the region.
here we describe current practices for ascVD screening and 
management among hiV clinics in lMics in asia. Our data will 
inform current and future research in the region and help poli-
cymakers develop more effective strategies to prevent and manage 
ascVD among PlhiV.
Methods
The international epidemiology Databases to evaluate aiDs (ieDea; 
www.iedea.org) is a global consortium that includes cohorts located 
in asia-Pacific, caribbean, south and north america, and central, 
east, southern and West africa [17–20]. ieDea provides a unique 
platform for evaluating standard practices and resource allocation 
in hiV cohorts in these regions. in 2016, a survey of lMic (as 
defined by World Bank [21]) sites in ieDea was conducted to 
assess site capacity for non-communicable disease screening and 
management [22–24]. a follow-up survey was conducted in 2018 
across sites in the ieDea asia-Pacific network to further evaluate 
screening and management practices for ascVD. We have assessed 
the results from both surveys.
investigators from ieDea developed and standardised a 302-ques-
tion survey on site resources, lifestyle assessment and education 
practices, screening and management of non-communicable 
diseases (hypertension, diabetes, kidney and pulmonary disease, 
mental health disorders and cancer), care for paediatric and ado-
lescent patients, availability of vaccinations, imaging, surgery 
and medicines and routine data collection procedures. The ieDea 
site capacity survey is available from the authors on request. 
Multilingual versions of the survey were implemented using 
research electronic Data capture (reDcap), a secure, web-based 
application designed to support data capture for research studies 
(www.project-redcap.org). reDcap was developed at the Van-
derbilt institute for clinical and Translational research. it provides 
an interface for validated data entry, audit trails for tracking data 
manipulation, and automated import and export procedures to 
common statistical packages [25]. separate reDcap databases 
were created for each of the participating regions and could be 
completed directly online or transferred from paper copies. regional 
data centres coordinated distribution to and completion of the 
survey by the sites. clinical site investigators affiliated with the 
ieDea regional networks were primarily responsible for completing 
the surveys. Data collection for ieDea asia-Pacific sites was com-
pleted by October 2016.
investigators from ieDea asia-Pacific developed an additional 
66-question survey to supplement the above mentioned site 
capacity survey. The survey containing the additional questions 
is available from the authors on request. Questions related to 
hyperlipidaemia screening and management, ascVD risk assess-
ment and management, chronic ischaemic stroke management, 
and access to lipid lowering and anti-diabetic medicines. although 
ascVD risk assessment tools are limited in their capacity to predict 
stroke risk accurately [26], we did not enquire about whether 
sites used additional means to assess stroke risk to prevent the 
survey becoming overly burdensome. an english version of the 
survey was implemented using reDcap, which allowed data to 
be entered directly online. sites could also complete the survey 
on paper and send scanned files to the ieDea asia-Pacific coor-
dinating centre (TreaT asia/amfar, Bangkok, Thailand) for data 
entry. clinical site investigators and data managers affiliated with 
ieDea asia-Pacific were primarily responsible for completing the 
surveys. Data collection was completed by June 2018. an addi-
tional question on beta-blocker availability was put to the sites 
via email in October 2019.
analysis
all 16 lMic sites in ieDea asia-Pacific participated in the global 
site capacity and regional ascVD surveys. countries included 
were Thailand (four sites), china (two sites), india (two sites), 
indonesia (two sites), Malaysia (two sites), Vietnam (two sites), 
cambodia (one site) and the Philippines (one site). Data from 
both surveys were combined and responses evaluated for incon-
sistencies, which were resolved through direct communication 
with site data managers. The results were split into eight categories: 
(1) general site characteristics; (2) risk factor assessment and 
patient education practices; (3) hypertension screening and man-
agement; (4) hyperlipidaemia screening and management; (5) 
diabetes screening and management; (6) ascVD risk assessment 
and management, and chronic ischaemic stroke management; 
(7) availability of clinical testing and procedure; and (8) availability 
of medicines.
Results
general site characteristics
sites were mostly (81%) based in urban public referral hospitals. 
seventy-five percent were linked to an academic medical centre. 
The median number of active outpatients was 2649 (interquartile 
range 1500–7500) and total number of active outpatients across 
all sites was 81,426. cardiology services were within the hiV 
clinic itself or available in the same facility for 75% of sites.
risk factor assessment and patient education practices
approximately half of sites had protocols to assess tobacco 
(50%), alcohol (50%) and other substance use (56%), as well 
as family history of chronic illnesses (50%). Protocols for assessing 
physical inactivity and obesity were in place at 31% and 38% 
of sites, respectively. Most sites provided educational material to 
patients on tobacco (75%), alcohol (69%) and other substance 
use (56%), physical inactivity (63%), and obesity and nutri-
tion (69%). The most common means of education was patient 
counselling (Table 1).
hypertension screening and management
ninety-four percent of sites reported performing routine screening 
for hypertension, with 64% indicating that they had a protocol 
in place (Table 2). Most sites (88%) did not have any selection 
criteria for performing hypertension screening and most (81%) 
conducted screening at every visit. Fifty percent of sites had a 
protocol in place for hypertension management.
hyperlipidaemia screening and management
all sites reported performing routine screening for hyperlipidaemia, 
with 44% having a protocol in place. available screening tests 
included total cholesterol (75% of sites), high-density lipoprotein 
cholesterol (63% of sites), low-density lipoprotein cholesterol 
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Table 1. assessment and patient education for individual risk factors (N=16)
Characteristic Tobacco use
n (%)
Alcohol use
n (%)
Other 
substance use
n (%)
Physical 
inactivity
n (%)
Obesity and 
nutrition
n (%)
Family history 
of chronic 
illness
Written protocol in place to assess 8 (50) 8 (50) 9 (56) 5 (31) 6 (38) 8 (50%)
educational material provided to patients 12 (75) 11 (69) 9 (56) 10 (63) 11 (69) na
Primary patient education method used
 counselling 5 (31) 5 (31) 3 (19) 5 (31) 5 (31) na
 group education 1 (6) 1 (6) 1 (6) 1 (6) 2 (13) na
 referral 1 (6) 1 (6) 1 (6) 0 (0) 2 (13) na
 Written information 3 (19) 2 (13) 3 (19) 1 (6) 1 (6) na
 Unspecified 2 (13) 2 (13) 1 (6) 3 (19) 1 (6) na
Table 2. hypertension screening and management (N=16)
routine screening for hypertension 15 (94)
Protocol for hypertension screening in place 9 (56)
screening tests useda
 Manual blood pressure measurement 9 (56)
 automated blood pressure measurement 8 (50)
 ambulatory 24-hour blood pressure monitoring 2 (13)
Patients assessed for hypertension
 all 14 (88)
 high-risk groups 0 (0)
 Other selection 0 (0)
 Undefined 2 (13)
Timing of hypertension screeninga
 at enrolment into care 5 (31)
 at antiretroviral therapy initiation 4 (25)
 Yearly 1 (6)
 at every visit 13 (81)
number of patients screened for hypertension per month
 0–100 1 (6)
 101–250 3 (19)
 251–500 2 (13)
 >500 8 (50)
 Uncertain 2 (13)
Protocol for hypertension management 8 (50)
location of hypertension management
 Within hiV clinic 11 (69)
 in same facility but not in hiV clinic 3 (19)
 Off site 2 (13)
 Undefined 0 (0)
 not available 0 (0)
staff primarily responsible for hypertension management
 hiV physician 10 (63)
 non-hiV physician 0 (0)
 nurse 0 (0)
 nurse assistant 1 (6)
 Other clinical staff 0 (0)
 non-clinical staff 0 (0)
 Uncertain 5 (31)
Training received in past 2 years for staff managing 
hypertension
10 (63)
Characteristic n (%) Characteristic n (%)
a respondents could select more than one option.
(69% of sites) and triglycerides (75% of sites). a protocol for 
hyperlipidaemia management was in place at 69% of sites. Further 
details on hyperlipidaemia screening and management procedures 
are shown in Table 3.
Diabetes screening and management
eighty-eight percent of sites reported performing routine screen-
ing for diabetes, with 56% indicating that they had a protocol 
in place (Table 4). The most frequent method used for diabetes 
screening was a fasting plasma glucose measurement (81% of 
sites). Fifty percent of sites had a protocol in place for diabetes 
management.
atherosclerotic cardiovascular disease risk assessment and 
management, and chronic ischaemic stroke management
routine assessment of ascVD risk was reported by 94% of sites, 
of which 25% reported having a protocol of any kind in place 
and 6%, a protocol specifically for PlhiV (Table 5). The most 
commonly used risk equations were Framingham (56%) and the 
american college of cardiology and american heart association 
pooled cohort (50%; respondents could select more than one 
option). nineteen percent of sites reported assessing ascVD risk 
among all patients and 63%, only among high-risk groups. a 
protocol for managing patients at high risk of ascVD was in 
place at 19% of sites, and 6% of sites had an hiV-specific pro-
tocol. Thirty-eight percent of sites reported having a protocol 
for chronic ischaemic stroke management; however, no site had 
a protocol specifically for PlhiV.
clinical testing and procedure availability
Blood pressure monitoring was available in all but one (94%) of 
the sites surveyed. Other tests and procedures were usually 
available either within the hiV clinic itself or in the same facility 
as the hiV clinic: glycosylated haemoglobin (hba1c, 81%), fasting 
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Table 3. hyperlipidaemia screening and management (N=16)
routine screening for hyperlipidaemia 16 (100)
Protocol for hyperlipidaemia screening 7 (44)
screening tests useda
 Fasting blood lipids 15 (94)
 non-fasting blood lipids 1 (6)
 Total cholesterol 12 (75)
 high-density lipoprotein (hDl) cholesterol 10 (63)
 low-density lipoprotein (lDl) cholesterol 11 (69)
 Triglycerides 12 (75)
Patients assessed for hyperlipidaemia
 all 11 (69)
 high-risk groups 2 (13)
 Other selection 3 (19)
 Undefined 0 (0)
Timing of hyperlipidaemia screeninga
 at enrolment into care 3 (19)
 at antiretroviral therapy initiation 3 (19)
 Yearly 13 (81)
 at every visit 1 (6)
number of patients screened for hyperlipidaemia per month
 0–100 3 (19)
 101–250 4 (25)
 251–500 4 (25)
 >500 3 (19)
 Uncertain 2 (13)
location of hyperlipidaemia screening
 Within hiV clinic 13 (81)
 in same facility but not in hiV clinic 2 (13)
 Off site 0 (0)
 Undefined 1 (6)
 not available 0 (0)
staff primarily responsible for hyperlipidaemia screening
 hiV physician 15 (94)
 non-hiV physician 0 (0)
 nurse 0 (0)
 nurse assistant 0 (0)
 Other clinical staff 1 (6)
 non-clinical staff 0 (0)
 Uncertain 0 (0)
Payment of hyperlipidaemia screening costs
 Patient only 5 (31)
 Full public funding 6 (38)
 co-payment (patient and public) 4 (25)
 Mixture of all 1 (6)
Protocol for hyperlipidaemia management 11 (69)
location of hyperlipidaemia management
 Within hiV clinic 14 (88)
 in same facility but not in hiV clinic 1 (6)
 Off site 0 (0)
 Undefined 0 (0)
 not available 1 (6)
staff primarily responsible for hyperlipidaemia 
management
 hiV physician 13 (81)
 non-hiV physician 0 (0)
 nurse 0 (0)
 nurse assistant 0 (0)
 Other clinical staff 1 (6)
 non-clinical staff 2 (13)
 Uncertain 0 (0)
Training received in past 2 years for staff managing 
hyperlipidaemia
10 (63)
Payment of hyperlipidaemia management costs 5 (31)
 Patient only 4 (25)
 Full public funding 6 (38)
 co-payment (patient and public) 1 (6)
 Mixture of all
Characteristic n (%) Characteristic n (%)
a respondents could select more than one option.
Table 4. Diabetes screening and management (N=16)
routine screening for diabetes 14 (88%)
Protocol for diabetes screening in place 9 (56%)
screening tests useda
 random plasma glucose measurement 7 (44%)
 Fasting plasma glucose measurement 13 (81%)
 2-hour plasma glucose tolerance test 4 (25%)
 hba1c 6 (38%)
Patients assessed for diabetes
 all 9 (56%)
 high-risk groups 2 (13%)
 Other selection 0 (0%)
 Undefined 3 (19%)
Timing of diabetes screeninga
 at enrolment into care 5 (31%)
 at antiretroviral therapy initiation 5 (31%)
 Yearly 4 (25%)
 at every visit 3 (19%)
number of patients screened for diabetes per month
 0–100 6 (38%)
 101–250 5 (31%)
 251–500 1 (6%)
 >500 3 (19%)
 Uncertain 1 (6%)
Characteristic n (%) Characteristic n (%)
Original researchJournal of Virus Eradication 2020; 6 : 11–18
atherosclerotic cardiovascular disease screening and management protocols among adult hiV clinics in asia 15
Table 5. ascVD risk assessment and management, and chronic ischaemic stroke management (N=16)
routine assessment of ascVD risk 15 (94)
Protocol for ascVD risk assessment 4 (25)
 hiV-specific protocol 1 (6)
cardiovascular disease risk calculators useda
 Data collection on adverse events of anti-hiV drugs 
(D:a:D)
2 (13)
 Framingham 9 (56)
 american college of cardiology 8 (50)
 Other 0 (0)
Patients assessed for ascVD risk
 all 3 (19)
 high-risk groups 10 (63)
 Other selection 2 (13)
 none 1 (6)
Timing of ascVD assessmenta
 at enrolment into care 4 (25)
 at antiretroviral therapy initiation 2 (13)
 Yearly 9 (56)
 at every visit 0 (0)
number of patients assessed for ascVD risk per month
 0–100 8 (50)
 101–250 2 (13)
 251–500 2 (13)
 >500 1 (6)
 Uncertain 3 (19)
location of ascVD risk assessment
 Within hiV clinic 13 (81)
 in same facility but not in hiV clinic 1 (6)
 Off site 0 (0)
 Undefined 1 (6)
 not available 1 (6)
staff primarily responsible for ascVD risk assessment
 hiV physician 13 (81)
 non-hiV physician 0 (0)
 nurse 1 (6)
 nurse assistant 0 (0)
 Other clinical staff 0 (0)
 non-clinical staff 1 (6)
 Uncertain 1 (6)
Protocol for managing those with high risk of ascVD 3 (19)
 hiV-specific protocol 1 (6)
Protocol for chronic ischaemic stroke management 6 (38)
 hiV-specific protocol 0 (0)
location of chronic ischaemic stroke management
 Within hiV clinic 4 (25)
 in same facility but not in hiV clinic 9 (56)
 Off site 2 (13)
 Undefined 0 (0)
 not available 1 (6)
staff primarily responsible for chronic ischaemic stroke 
management
 hiV physician 4 (25)
 non-hiV physician 10 (63)
 nurse 0 (0)
 nurse assistant 0 (0)
 Other clinical staff 1 (6)
 non-clinical staff 1 (6)
 Uncertain 0 (0)
Training received in past 2 years for staff managing 
chronic ischaemic stroke
6 (38)
Payment of chronic ischaemic stroke management costs
 Patient only 7 (44)
 Full public funding 4 (25)
 co-payment (patient and public) 4 (25)
 Mixture of all 1 (6)
Characteristic n (%) Characteristic n (%)
a respondents could select more than one option. ascVD: atherosclerotic cardiovascular disease. 
Protocol for diabetes management 8 (50%)
location of diabetes management
 Within hiV clinic 9 (56%)
 in same facility but not in hiV clinic 4 (25%)
 Off site 1 (6%)
 Undefined 1 (6%)
 not available 1 (6%)
staff primarily responsible for diabetes management
 hiV physician 9 (56%)
 non-hiV physician 0 (0%)
 nurse 0 (0%)
 nurse assistant 0 (0%)
 Other clinical staff 0 (0%)
 non-clinical staff 0 (0%)
 Uncertain 7 (44%)
Training received in past 2 years for staff managing 
diabetes
10 (63)
Characteristic n (%) Characteristic n (%)
Table 4. Diabetes screening and management (N=16) (continued)
a respondents could select more than one option. hba1c: glycosylated haemoglobin.
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Table 6. Test and procedure availability (N=16)
Availability and 
cost
Blood 
pressure 
monitor
n (%)
HbA1c
n (%)
Fasting plasma 
glucose
n (%)
Oral glucose 
tolerance test
n (%)
Random 
plasma 
glucose
n (%)
Digital 
photographya
n (%)
Point of care 
diabetes 
testing
n (%)
Computed 
tomography 
scan
n (%)
availability
 Within hiV 
clinic
15 (94) 9 (56) 12 (75) 6 (38) 11 (69) 1 (6) 10 (63) 3 (19)
 in same facility 
but not in hiV 
clinic
0 (0) 4 (25) 2 (13) 7 (44) 3 (19) 4 (25) 2 (13) 10 (63)
 Off site 0 (0) 2 (13) 1 (6) 1 (6) 0 (0) 3 (19) 2 (13) 2 (13)
 not available 1 (6) 1 (6) 1 (6) 2 (13) 2 (13) 8 (50) 2 (13) 1 (6)
Procedure or test 
free for patients
11 (69) 5 (31) 7 (44) 3 (19) 5 (31) 3 (19) 5 (31) 4 (25)
Brain 
MRI
Computed 
tomography 
angiogram
Echocardiogram ECG Cardiac 
stress testb
24-hour 
Holter 
monitor
Carotid  
duplex/
ultrasound
Cardiac 
catheterisation
availability
 Within hiV 
clinic
3 (19) 3 (19) 3 (19) 7 (44) 2 (13) 2 (13) 2 (13) 2 (13)
 in same facility 
but not in hiV 
clinic
10 (63) 8 (50) 11 (69) 6 (38) 10 (63) 9 (56) 9 (56) 8 (50)
 Off site 2 (13) 4 (25) 1 (6) 1 (6) 2 (13) 3 (19) 3 (19) 4 (25)
 not available 1 (6) 1 (6) 1 (6) 2 (13) 2 (13) 2 (13) 2 (13) 2 (13)
Procedure or test 
free for patients
4 (25) 4 (25) 4 (25) 5 (31) 3 (19) 3 (19) 3 (19) 2 (13)
Cardiac 
troponin
Creatine 
kinase MB 
isoenzyme
Creatine 
phosphokinase
Cerebral 
thrombectomy
Stroke 
rehabilitation
Coronary 
bypass or 
stenting
availability
 Within hiV 
clinic
6 (38) 6 (38) 6 (38) 0 (0) 1 (6) 0 (0)
 in same facility 
but not in hiV 
clinic
6 (38) 6 (38) 6 (38) 8 (50) 11 (69) 8 (50)
 Off site 2 (13) 2 (13) 2 (13) 4 (25) 3 (19) 6 (38)
 not available 2 (13) 2 (13) 2 (13) 4 (25) 1 (6) 2 (13)
Procedure or test 
free for patients
3 (19) 3 (19) 3 (19) 3 (19) 5 (31) na
a For remote diagnosis of diabetic retinopathy. 
b  any form of cardiac stress test. ecg: electrocardiogram; hba1c: glycosylated haemoglobin; MB: myocardial band; Mri: magnetic resonance imaging; na: not 
assessed.
plasma glucose (88%), oral glucose tolerance test (81%), random 
plasma glucose (88%), point-of-care diabetes testing (75%), 
computed tomography scan (81%), brain magnetic resonance 
imaging (81%), computed tomography angiogram (68%), echocar-
diogram (88%), electrocardiogram (81%), any form of cardiac 
stress test (75%), 24-hour holter monitor (69%), carotid duplex 
or ultrasound (69%), cardiac catheterisation (63%), cardiac tro-
ponin (75%), creatine kinase myocardial band isoenzyme (75%), 
creatine phosphokinase (75%) and stroke rehabilitation (75%). 
cerebral thrombectomy and coronary bypass or stenting were 
available within the same facility as the hiV clinic at 50% of 
sites. Digital photography for remote diagnosis of diabetic retin-
opathy was available either within the hiV clinic, within the same 
facility as the hiV clinic or off site at 50% of sites. Blood pressure 
monitoring was free to patients at 69% of sites; however, most 
sites required patients to pay some or all the associated costs 
for other procedures (Table 6).
Medication availability
Medications available in the clinic or within the same facility to 
treat ascVD-associated conditions included thiazides (88%), 
angiotensin-converting enzyme inhibitors (81%), calcium channel 
blockers (88%), beta-blockers (94%), statins (94%), fibrates 
(88%), ezetimibe (56%), aspirin (88%), P2Y12 inhibitors (81%), 
alteplase (56%) and sulphonylureas (94%). Further details on 
medication availability are provided in Table 7.
Discussion
The surveys of 16 hiV clinics in lMics in asia revealed several 
gaps in ascVD diagnosis and management practices, in particular, 
a lack of ascVD screening and management protocols. To our 
knowledge, this is the first study to report the capacity of hiV 
clinics in asia to manage and screen for ascVD.
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Table 7. Medication availability (N=16)
Characteristic Aspirin
n (%)
P2Y12 
inhibitors
n (%)
Alteplase
n (%)
Atorvastatin
n (%)
Fluvostatin
n (%)
Lovastatin
n (%)
Pitavastatin
n (%)
Pravastatin
n (%)
availability
 Within hiV clinic 3 (19) 6 (38) 0 (0) 9 (56) 3 (19) 2 (13) 6 (38) 4 (25)
 in same facility but not in 
hiV clinic
11 (69) 7 (44) 9 (56) 5 (31) 3 (19) 5 (31) 5 (31) 6 (38)
 Off site 1 (6) 2 (13) 4 (25) 1 (6) 3 (19) 3 (19) 1 (6) 3 (19)
 not available 1 (6) 1 (6) 3 (19) 1 (6) 7 (44) 6 (38) 4 (25) 3 (19)
Rosuvastatin Simvastatin Gemfibrozil Fenofibrate Clofibrate Ezetimibe Thiazides ACE-
inhibitors
availability
 Within hiV clinic 8 (50) 7 (44) 7 (44) 9 (56) 2 (13) 5 (31) 10 (63) 9 (56)
 in same facility but not in 
hiV clinic
5 (31) 6 (38) 5 (31) 5 (31) 5 (31) 4 (25) 4 (25) 4 (25)
 Off site 1 (6) 2 (13) 2 (13) 1 (6) 2 (13) 4 (25) 0 (0) 1 (6)
 not available 2 (13) 1 (6) 2 (13) 1 (6) 7 (44) 3 (19) 2 (13) 2 (13)
CCBs Beta-
blockers
Sulphonylureas Meglitinides AGIs Glitazones DPP-4 
inhibitors
Incretin 
mimetics
availability
 Within hiV clinic 10 (63) 4 (25) 8 (50) 3 (19) 4 (25) 6 (38) 5 (31) 2 (13)
 in same facility but not in 
hiV clinic
4 (25) 11 (69) 7 (44) 8 (50) 7 (44) 6 (38) 7 (44) 6 (38)
 Off site 0 (0) 1 (6) 1 (6) 2 (13) 3 (19) 3 (19) 2 (13) 3 (19)
 not available 2 (13) 0 (0) 0 (0) 3 (19) 2 (13) 1 (6) 2 (13%) 5 (31%)
ace: angiotensin-converting enzyme; agis: alpha-glucosidase inhibitors; ccBs: calcium channel blockers; DPP: dipeptidyl peptidase.
For each of the major ascVD risk factors assessed, approximately 
half of the surveyed sites indicated they had an assessment pro-
tocol in place. Between 56% and 75% of the sites provided 
some form of education to patients on these risk factors, indicating 
room for improvement. education empowers patients and com-
munity members to seek care and to better manage their health 
[15]. in comparison with a similar survey among hiV treatment 
sites in Tanzania [27], education provision among our asian sites 
was higher for tobacco use (75% vs 57%), lower for alcohol use 
(69% vs 86%), and slightly higher for obesity and nutrition (69% 
vs 64%).
routine screening for hypertension, hyperlipidaemia, diabetes 
and ascVD risk was common, and sites had excellent access 
to blood pressure monitors, lipid and fasting plasma glucose 
testing, and appropriate ascVD risk equations. however, only 
64% of sites had a protocol in place for hypertension screening 
and fewer had protocols to screen for hyperlipidaemia, diabetes or 
ascVD risk. in asia and elsewhere, primary care systems with well- 
established protocols have proven to be effective in non-commu-
nicable disease prevention and management [28–30]. Protocols 
help to standardise medical care and optimise the utility of equip-
ment, laboratory testing and medications. For hiV or primary care 
clinics, protocols can also assist in deciding appropriate patient 
referral for a non-communicable disease-related complication.
Many sites also lacked a protocol for the management of hyper-
tension, hyperlipidaemia, diabetes, high ascVD risk and chronic 
stroke. This finding is consistent with other studies from resource-
limited countries reporting findings from hiV [27] and primary 
care clinics [31,32]. importantly, the availability of medications 
to treat these conditions was generally good. as an example, 
while we found 94% of sites had statins available either within 
the hiV clinic or in the same facility as the hiV clinic, leung 
et al. reported that less than 10% of the hiV clinics they had 
surveyed in Tanzania could provide simvastatin [27]. it was also 
encouraging to find that coronary bypass or stenting and stroke 
rehabilitation services were available at 88% and 94% of the 
surveyed sites, respectively.
Patient management of hypertension, hyperlipidaemia, diabetes 
and chronic stroke was usually carried out by an hiV physician. 
This is becoming more common in lMics; however, in high-
income countries, where integrated care has typically focused 
on better management of broad groups of people with multiple 
morbidities, hiV physicians may not have as much autonomy 
regarding their patient cVD care [33]. For 38% to 63% of sites, 
the staff member primarily responsible for patient management 
had received training in the last 2 years. Patients often had 
to pay some or all of the costs associated with diagnosis and 
management. ensuring clinics are adequately staffed to address 
the growing ascVD burden among PlhiV is critical. Moreover, 
healthcare workers must be adequately trained, encouraged to 
explore novel models of care and incentivised to continue devel-
oping their career track [15]. This study indicates that staff at 
the surveyed clinics have sufficient tools available to diagnose 
and manage patients appropriately.
There are several limitations to this study. First, the hiV clinics 
included may not be representative of hiV care across asia, par-
ticularly in more rural areas. second, our study is based on self-
reported data collected cross-sectionally, which may be subject 
to recall and desirability biases. Finally, we have captured infor-
mation only on the service availability and not their quality, uptake 
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or coverage. Further studies examining the quality of ascVD 
care provided in asian hiV clinics and impact of ascVD preven-
tion and care initiatives among PlhiV are warranted.
This study shows ascVD care is generally well integrated among 
urban hiV centres in lMics in asia. The consistent availability of 
clinical screening, diagnostic testing and procedures, and ascVD 
medication is a strength in the current system that should be lever-
aged to improve implementation of cardiovascular care protocols.
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